Characterizing Patients and Treatment Patterns in Moderate-to-severe Atopic Dermatitis in Finland: A Population-based Study Using National Health Data

This observational study evaluated demographics, disease characteristics, and treatment patterns in children, adolescents, and adults with moderate-to-severe atopic dermatitis (AD) and compared comorbidities (adults only) and healthcare resource use with those of matched reference subjects without m...

Full description

Saved in:
Bibliographic Details
Published inActa dermato-venereologica Vol. 105; p. adv41244
Main Authors Remitz, Anita, Peltonen, Essi J., Korhonen, Laura, Nortamo, Pekka, Iso-Mustajärvi, Ilona, Prami, Tuire, Oinonen, Lasse, Gittens, Beatrice, Von Arx, Lill-Brith, Porsdal, Vibeke
Format Journal Article
LanguageEnglish
Published Sweden MJS Publishing, on behalf of the Society for Publication of Acta Dermato-Venereologica 24.04.2025
Medical Journals Sweden
Subjects
Online AccessGet full text
ISSN0001-5555
1651-2057
1651-2057
DOI10.2340/actadv.v105.41244

Cover

Abstract This observational study evaluated demographics, disease characteristics, and treatment patterns in children, adolescents, and adults with moderate-to-severe atopic dermatitis (AD) and compared comorbidities (adults only) and healthcare resource use with those of matched reference subjects without moderate-to-severe AD in Finland between 2016 and 2020. A total of 68,216 patients with moderate-to-severe AD and a reference population of 338,325 people without moderate-to-severe AD were identified and included in the study. Among children aged 0–11 years in the moderate-to-severe AD cohort, most were diagnosed with AD and were identified to have moderate-to-severe AD before they reached 4 years of age (92.4% and 79.3%, respectively). Atopic disorders and psychiatric, gastrointestinal, and other diseases were more common in adults with moderate-to-severe AD than in the reference population. Regardless of age, patients with moderate-to-severe AD had a higher number of primary and secondary healthcare visits annually compared with the reference population. Across all 3 age groups, topical corticosteroids and emollients were the 2 categories of AD medications most frequently used throughout the study period. In adults, the use of methotrexate and dupilumab increased over the course of the study. Moderate-to-severe AD affects people of all ages in Finland.
AbstractList This observational study evaluated demographics, disease characteristics, and treatment patterns in children, adolescents, and adults with moderate-to-severe atopic dermatitis (AD) and compared comorbidities (adults only) and healthcare resource use with those of matched reference subjects without moderate-to-severe AD in Finland between 2016 and 2020. A total of 68,216 patients with moderate-to-severe AD and a reference population of 338,325 people without moderate-to-severe AD were identified and included in the study. Among children aged 0–11 years in the moderate-to-severe AD cohort, most were diagnosed with AD and were identified to have moderate-to-severe AD before they reached 4 years of age (92.4% and 79.3%, respectively). Atopic disorders and psychiatric, gastrointestinal, and other diseases were more common in adults with moderate-to-severe AD than in the reference population. Regardless of age, patients with moderate-to-severe AD had a higher number of primary and secondary healthcare visits annually compared with the reference population. Across all 3 age groups, topical corticosteroids and emollients were the 2 categories of AD medications most frequently used throughout the study period. In adults, the use of methotrexate and dupilumab increased over the course of the study. Moderate-to-severe AD affects people of all ages in Finland.
This observational study evaluated demographics, disease characteristics, and treatment patterns in children, adolescents, and adults with moderate-to-severe atopic dermatitis (AD) and compared comorbidities (adults only) and healthcare resource use with those of matched reference subjects without moderate-to-severe AD in Finland between 2016 and 2020. A total of 68,216 patients with moderate-to-severe AD and a reference population of 338,325 people without moderate-to-severe AD were identified and included in the study. Among children aged 0–11 years in the moderate-to-severe AD cohort, most were diagnosed with AD and were identified to have moderate-to-severe AD before they reached 4 years of age (92.4% and 79.3%, respectively). Atopic disorders and psychiatric, gastrointestinal, and other diseases were more common in adults with moderate-to-severe AD than in the reference population. Regardless of age, patients with moderate-to-severe AD had a higher number of primary and secondary healthcare visits annually compared with the reference population. Across all 3 age groups, topical corticosteroids and emollients were the 2 categories of AD medications most frequently used throughout the study period. In adults, the use of methotrexate and dupilumab increased over the course of the study. Moderate-to-severe AD affects people of all ages in Finland. Analysis of real-world data provides insights into characteristics of patients with moderate-to-severe atopic dermatitis and the medical treatment they receive. This nationwide study identified and analysed 68,216 patients with moderate-to-severe atopic dermatitis in Finland during the years 2016–2020. Their healthcare resource use was compared with that in a reference sample of 338,325 people without moderate-to-severe atopic dermatitis. Findings demonstrate that moderate-to-severe atopic dermatitis is associated with increased disease burden and healthcare resource use in all age groups. It is therefore imperative to aim for improved control of atopic dermatitis.
This observational study evaluated demographics, disease characteristics, and treatment patterns in children, adolescents, and adults with moderate-to-severe atopic dermatitis (AD) and compared comorbidities (adults only) and healthcare resource use with those of matched reference subjects without moderate-to-severe AD in Finland between 2016 and 2020. A total of 68,216 patients with moderate-to-severe AD and a reference population of 338,325 people without moderate-to-severe AD were identified and included in the study. Among children aged 0-11 years in the moderate-to-severe AD cohort, most were diagnosed with AD and were identified to have moderate-to-severe AD before they reached 4 years of age (92.4% and 79.3%, respectively). Atopic disorders and psychiatric, gastrointestinal, and other diseases were more common in adults with moderate-to-severe AD than in the reference population. Regardless of age, patients with moderate-to-severe AD had a higher number of primary and secondary healthcare visits annually compared with the reference population. Across all 3 age groups, topical corticosteroids and emollients were the 2 categories of AD medications most frequently used throughout the study period. In adults, the use of methotrexate and dupilumab increased over the course of the study. Moderate-to-severe AD affects people of all ages in Finland.This observational study evaluated demographics, disease characteristics, and treatment patterns in children, adolescents, and adults with moderate-to-severe atopic dermatitis (AD) and compared comorbidities (adults only) and healthcare resource use with those of matched reference subjects without moderate-to-severe AD in Finland between 2016 and 2020. A total of 68,216 patients with moderate-to-severe AD and a reference population of 338,325 people without moderate-to-severe AD were identified and included in the study. Among children aged 0-11 years in the moderate-to-severe AD cohort, most were diagnosed with AD and were identified to have moderate-to-severe AD before they reached 4 years of age (92.4% and 79.3%, respectively). Atopic disorders and psychiatric, gastrointestinal, and other diseases were more common in adults with moderate-to-severe AD than in the reference population. Regardless of age, patients with moderate-to-severe AD had a higher number of primary and secondary healthcare visits annually compared with the reference population. Across all 3 age groups, topical corticosteroids and emollients were the 2 categories of AD medications most frequently used throughout the study period. In adults, the use of methotrexate and dupilumab increased over the course of the study. Moderate-to-severe AD affects people of all ages in Finland.
Author Korhonen, Laura
Remitz, Anita
Nortamo, Pekka
Gittens, Beatrice
Von Arx, Lill-Brith
Oinonen, Lasse
Porsdal, Vibeke
Iso-Mustajärvi, Ilona
Prami, Tuire
Peltonen, Essi J.
Author_xml – sequence: 1
  givenname: Anita
  surname: Remitz
  fullname: Remitz, Anita
– sequence: 2
  givenname: Essi J.
  surname: Peltonen
  fullname: Peltonen, Essi J.
– sequence: 3
  givenname: Laura
  surname: Korhonen
  fullname: Korhonen, Laura
– sequence: 4
  givenname: Pekka
  surname: Nortamo
  fullname: Nortamo, Pekka
– sequence: 5
  givenname: Ilona
  surname: Iso-Mustajärvi
  fullname: Iso-Mustajärvi, Ilona
– sequence: 6
  givenname: Tuire
  surname: Prami
  fullname: Prami, Tuire
– sequence: 7
  givenname: Lasse
  surname: Oinonen
  fullname: Oinonen, Lasse
– sequence: 8
  givenname: Beatrice
  surname: Gittens
  fullname: Gittens, Beatrice
– sequence: 9
  givenname: Lill-Brith
  surname: Von Arx
  fullname: Von Arx, Lill-Brith
– sequence: 10
  givenname: Vibeke
  surname: Porsdal
  fullname: Porsdal, Vibeke
BackLink https://www.ncbi.nlm.nih.gov/pubmed/40271985$$D View this record in MEDLINE/PubMed
BookMark eNpVks1uEzEUhS1URH_gAdggL9lM8O_MmA2K0pZWKlCJdm059p3E1cQOthOpPAjPi5OUinpj3XPP_a5kn1N0FGIAhN5TMmFckE_GFuO2ky0lciIoE-IVOqGtpA0jsjtCJ4QQ2sh6jtFpzg-1ZJL2b9CxIKyjqpcn6M9saVLlQPK_fVjgW1M8hJKxCQ7fJTBlVcudXC0hYx_wt-ggmQJNiU2GLSTA0xLX3uJzSKs6X_zed-nDWCmf8RTfxvVmrJ0YmrnJ4PDPsnGP-D7vVn7fN8yIr8CMZYnPTTFv0evBjBnePd1n6P7y4m521dz8-Ho9m940VjBSGsdZr4RwLVekVwPQgXLimGPGSuKMdG0_SMaUasVg5sAGOSgGXW-tJfO-6_gZuj5wXTQPep38yqRHHY3XeyGmhTapeDuC7oStA7bnneBCQtu3RjCuWDfnrnMWKuvLgbXezFdQlVCSGV9AX3aCX-pF3GrKiKCd6ivh4xMhxV8byEWvfLYw1meEuMmaUyWYVETKav3w_7LnLf9-throwWBTzDnB8GyhRO_Sow_p0bv06H16-F-eZrt3
Cites_doi 10.1111/ijd.15912
10.1016/j.jaad.2022.01.009
10.1111/all.13401
10.1002/ski2.232
10.2340/actadv.v103.4447
10.2340/00015555-3165
10.1016/j.clindermatol.2021.08.021
10.1080/19490976.2022.2096995
10.2340/00015555-3257
10.2340/actadv.v102.2287
10.2340/00015555-3510
10.1016/j.jid.2017.03.029
10.12788/cutis.0831
10.1007/s40257-018-0383-4
10.1111/bjd.18296
10.1007/s40257-019-00453-7
10.1080/21556660.2019.1619570
10.5826/dpc.1104a146
10.2340/00015555-3369
10.1097/DER.0000000000000895
10.1002/jvc2.247
10.1111/jdv.18429
10.1016/j.jaad.2016.05.028
10.1016/S0140-6736(20)31286-1
ContentType Journal Article
Copyright 2025 The Author(s) 2025
Copyright_xml – notice: 2025 The Author(s) 2025
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOA
DOI 10.2340/actadv.v105.41244
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals (WRLC)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList

MEDLINE - Academic
MEDLINE
CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1651-2057
ExternalDocumentID oai_doaj_org_article_74c773c8374345e686a423927b3d7dce
PMC12041798
40271985
10_2340_actadv_v105_41244
Genre Journal Article
Observational Study
GeographicLocations Finland
GeographicLocations_xml – name: Finland
GroupedDBID ---
23M
36B
5GY
5RE
5VS
6J9
AAFWJ
AAYXX
ABDBF
ABOCM
ACGFO
ACUHS
AEGXH
AENEX
AIAGR
ALMA_UNASSIGNED_HOLDINGS
B0M
CITATION
CS3
DIK
E3Z
EAD
EAP
EBC
EBD
EBS
EBX
EJD
EMB
EMK
EMOBN
ESX
F5P
FIJ
GROUPED_DOAJ
GX1
H13
HF~
IPNFZ
KQ8
L7B
MSJ
OK1
P2P
P6G
RIG
RNS
RPM
SV3
TR2
TUS
~8M
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ID FETCH-LOGICAL-c420t-d328944d639089fe1f130d2d2ac50da5d68f5229964fabe2f5f92e78ccc0b8773
IEDL.DBID DOA
ISSN 0001-5555
1651-2057
IngestDate Wed Aug 27 01:19:00 EDT 2025
Thu Aug 21 18:26:37 EDT 2025
Wed Jul 02 04:50:10 EDT 2025
Thu May 29 04:59:36 EDT 2025
Sun Jul 06 05:03:56 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Language English
License https://creativecommons.org/licenses/by-nc/4.0
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c420t-d328944d639089fe1f130d2d2ac50da5d68f5229964fabe2f5f92e78ccc0b8773
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
Retired; affiliation at time study was conducted.
OpenAccessLink https://doaj.org/article/74c773c8374345e686a423927b3d7dce
PMID 40271985
PQID 3194259055
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_74c773c8374345e686a423927b3d7dce
pubmedcentral_primary_oai_pubmedcentral_nih_gov_12041798
proquest_miscellaneous_3194259055
pubmed_primary_40271985
crossref_primary_10_2340_actadv_v105_41244
PublicationCentury 2000
PublicationDate 20250424
PublicationDateYYYYMMDD 2025-04-24
PublicationDate_xml – month: 4
  year: 2025
  text: 20250424
  day: 24
PublicationDecade 2020
PublicationPlace Sweden
PublicationPlace_xml – name: Sweden
PublicationTitle Acta dermato-venereologica
PublicationTitleAlternate Acta Derm Venereol
PublicationYear 2025
Publisher MJS Publishing, on behalf of the Society for Publication of Acta Dermato-Venereologica
Medical Journals Sweden
Publisher_xml – name: MJS Publishing, on behalf of the Society for Publication of Acta Dermato-Venereologica
– name: Medical Journals Sweden
References 108820
108821
108822
108816
108817
108818
108819
108812
108813
108814
108815
108830
108831
108832
108833
108827
108828
108829
108823
108824
108825
108826
108841
108842
108843
108844
108840
108838
108839
108834
108835
108836
108837
108852
108810
108811
108850
108851
108809
108805
108849
108806
108807
108808
108845
108802
108846
108803
108847
108804
108848
References_xml – ident: 108824
  doi: 10.1111/ijd.15912
– ident: 108844
  doi: 10.1016/j.jaad.2022.01.009
– ident: 108811
  doi: 10.1111/all.13401
– ident: 108814
  doi: 10.1002/ski2.232
– ident: 108842
  doi: 10.2340/actadv.v103.4447
– ident: 108809
  doi: 10.2340/00015555-3165
– ident: 108815
  doi: 10.1002/ski2.232
– ident: 108846
  doi: 10.1016/j.clindermatol.2021.08.021
– ident: 108847
  doi: 10.1080/19490976.2022.2096995
– ident: 108805
  doi: 10.2340/00015555-3257
– ident: 108837
  doi: 10.2340/actadv.v102.2287
– ident: 108812
  doi: 10.2340/00015555-3510
– ident: 108810
  doi: 10.1111/all.13401
– ident: 108832
  doi: 10.1016/j.jid.2017.03.029
– ident: 108851
  doi: 10.12788/cutis.0831
– ident: 108813
  doi: 10.2340/00015555-3510
– ident: 108841
  doi: 10.2340/actadv.v103.4447
– ident: 108807
  doi: 10.1007/s40257-018-0383-4
– ident: 108849
  doi: 10.1111/bjd.18296
– ident: 108817
  doi: 10.1007/s40257-019-00453-7
– ident: 108820
  doi: 10.1080/21556660.2019.1619570
– ident: 108825
  doi: 10.1111/ijd.15912
– ident: 108822
  doi: 10.5826/dpc.1104a146
– ident: 108826
  doi: 10.2340/00015555-3369
– ident: 108833
  doi: 10.1097/DER.0000000000000895
– ident: 108836
– ident: 108838
  doi: 10.2340/actadv.v102.2287
– ident: 108804
  doi: 10.2340/00015555-3257
– ident: 108840
  doi: 10.1002/jvc2.247
– ident: 108827
  doi: 10.2340/00015555-3369
– ident: 108831
  doi: 10.1016/j.jid.2017.03.029
– ident: 108848
  doi: 10.1080/19490976.2022.2096995
– ident: 108806
  doi: 10.1007/s40257-018-0383-4
– ident: 108828
  doi: 10.1111/jdv.18429
– ident: 108821
  doi: 10.1080/21556660.2019.1619570
– ident: 108835
– ident: 108843
  doi: 10.1016/j.jaad.2022.01.009
– ident: 108816
  doi: 10.1007/s40257-019-00453-7
– ident: 108818
  doi: 10.1016/j.jaad.2016.05.028
– ident: 108839
  doi: 10.1002/jvc2.247
– ident: 108819
  doi: 10.1016/j.jaad.2016.05.028
– ident: 108850
  doi: 10.1111/bjd.18296
– ident: 108823
  doi: 10.5826/dpc.1104a146
– ident: 108830
– ident: 108802
  doi: 10.1016/S0140-6736(20)31286-1
– ident: 108852
  doi: 10.12788/cutis.0831
– ident: 108845
  doi: 10.1016/j.clindermatol.2021.08.021
– ident: 108834
  doi: 10.1097/DER.0000000000000895
– ident: 108803
  doi: 10.1016/S0140-6736(20)31286-1
– ident: 108808
  doi: 10.2340/00015555-3165
– ident: 108829
  doi: 10.1111/jdv.18429
SSID ssj0002518
Score 2.4141834
Snippet This observational study evaluated demographics, disease characteristics, and treatment patterns in children, adolescents, and adults with moderate-to-severe...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage adv41244
SubjectTerms Adolescent
Adrenal Cortex Hormones - therapeutic use
Adult
Age Factors
Aged
Atopic dermatitis
Child
Child, Preschool
clinical practice patterns
Comorbidity
Databases, Factual
Dermatitis, Atopic - diagnosis
Dermatitis, Atopic - drug therapy
Dermatitis, Atopic - epidemiology
Dermatologic Agents - administration & dosage
Dermatologic Agents - therapeutic use
Emollients - therapeutic use
Female
Finland - epidemiology
Humans
Infant
Infant, Newborn
Male
Middle Aged
observational study
Original Report
patient characteristics
Practice Patterns, Physicians' - trends
Severity of Illness Index
Young Adult
Title Characterizing Patients and Treatment Patterns in Moderate-to-severe Atopic Dermatitis in Finland: A Population-based Study Using National Health Data
URI https://www.ncbi.nlm.nih.gov/pubmed/40271985
https://www.proquest.com/docview/3194259055
https://pubmed.ncbi.nlm.nih.gov/PMC12041798
https://doaj.org/article/74c773c8374345e686a423927b3d7dce
Volume 105
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NSxwxFA_ioXgptrXt9kNS6KkQzeZjkultq12koHhQ8BYySQYHZFbcUWj_kP69fS-ZXdxS8NI5JoGE-b28j-Tl9wj5LKOxAboYB1vLQEt65r2QTPo2TE0A2Gt873x6Vp1cqh9X-upRqS_MCSv0wOXHHRoVjJEB4igllU6VrTxy1gnTwDQxJNS-vOarYGrUwWC1iw6GYFnDV-4zhVT80IfBx4eDB3AsDrD0stqwSJm4_1_e5t9Jk4-s0HyXPB_dRzory35BtlL_kjw7HS_IX5HfR2sC5l9glOh5oU1dUt9HerFKKsdmPAhc0q6nuRoaeJxsWDAwk-ku0dmwuO0CPU7Fn-3yuHnXYxbkVzqj5-uqXwytYKSYjfiT5vQDOjJt39Dywoke-8Hvkcv594ujEzaWXmBBCT6wKCEQUyqC_8Jt3aZpC7Yuiih80Dx6HSvbgucGwZJqfZNEq9taJIA9BN5YAOw12e4XfXpLaGNC46tgosZXq1x5k6oQjJQx1bYR1YR8Wf1-d1sYNhxEJoiVK1g5xMplrCbkGwK0Hojk2LkBRMaNIuOeEpkJ-bSC18FmwhsS36fF_dKBPgIdVnOtJ-RNgXs9FQTaZlpb6LEbgrCxls2evrvOhN1TwbHQm333P1b_nuwIrEHMFRPqA9ke7u7TR3CMhmY_74H9fGL1B7hXDaY
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Characterizing+Patients+and+Treatment+Patterns+in+Moderate-to-severe+Atopic+Dermatitis+in+Finland%3A+A+Population-based+Study+Using+National+Health+Data&rft.jtitle=Acta+dermato-venereologica&rft.au=Remitz%2C+Anita&rft.au=Peltonen%2C+Essi+J.&rft.au=Korhonen%2C+Laura&rft.au=Nortamo%2C+Pekka&rft.date=2025-04-24&rft.issn=0001-5555&rft.eissn=1651-2057&rft.volume=105&rft.spage=adv41244&rft_id=info:doi/10.2340%2Factadv.v105.41244&rft.externalDBID=n%2Fa&rft.externalDocID=10_2340_actadv_v105_41244
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0001-5555&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0001-5555&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0001-5555&client=summon